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Background: The human leukocyte antigen (HLA) region, the 3.8-Mb segment of the human genome at 6p21, has
been associated with more than 100 different diseases, mostly autoimmune diseases. Due to the complex nature of
HLA genes, there are difficulties in elucidating complete HLA gene sequences especially HLA gene haplotype
structures by the conventional sequencing method. We propose a novel, accurate, and cost-effective method for
generating phase-defined complete sequencing of HLA genes by using indexed multiplex next generation
sequencing.
Results: A total of 33 HLA homozygous samples, 11 HLA heterozygous samples, and 3 parents-child families were
subjected to phase-defined HLA gene sequencing. We applied long-range PCR to amplify six HLA genes (HLA-A, -C,
-B, DRB1, -DQB1, and –DPB1) followed by transposase-based library construction and multiplex sequencing with the
MiSeq sequencer. Paired-end reads (2 × 250 bp) derived from the sequencer were aligned to the six HLA gene
segments of UCSC hg19 allowing at most 80 bases mismatch. For HLA homozygous samples, the six amplicons of
an individual were pooled and simultaneously sequenced and mapped as an individual-tagging method. The
paired-end reads were aligned to corresponding genes of UCSC hg19 and unambiguous, continuous sequences
were obtained. For HLA heterozygous samples, each amplicon was separately sequenced and mapped as a gene-
tagging method. After alignments, we detected informative paired-end reads harboring SNVs on both forward and
reverse reads that are used to separate two chromosomes and to generate two phase-defined sequences in an
individual. Consequently, we were able to determine the phase-defined HLA gene sequences from promoter to 3′-
UTR and assign up to 8-digit HLA allele numbers, regardless of whether the alleles are rare or novel. Parent–child
trio-based sequencing validated our sequencing and phasing methods.
Conclusions: Our protocol generated phased-defined sequences of the entire HLA genes, resulting in high
resolution HLA typing and new allele detection.
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The human leukocyte antigen (HLA) region on the
chromosome 6p21 comprising six classical polymorphic
HLA genes and at least 132 protein coding genes plays
important roles in regulation of immune system as well
as fundamental molecular and cellular processes [1].
The completion of a continuous 3.6 Mb of HLA gen-
omic sequence together with annotation of 224 genes,
was first reported by The MHC Sequencing Consortium
in 1999 [2]. In addition, the MHC Haplotype Project* Correspondence: itinoue@nig.ac.jp
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distribution, and reproduction in any mediumconducted by the Sanger Institute provided genomic se-
quences and gene annotation of eight different HLA
haplotypes, which were registered in the UCSC hg19
and NCBI GRCh37 reference assembly [3-5]. This 3.6
Mb segment occupies only 0.13% of the human genome
but is associated with more than 100 different diseases,
mostly autoimmune diseases such as type I diabetes,
rheumatoid arthritis, psoriasis, and atopic asthma. Re-
cently, HLA genes attracted special attentions, because
specific alleles of HLA genes are strongly associated with
drug hypersensitivity induced by specific drugs. For
example, strong associations between carbamazepine-
induced Stevens-Johnson syndrome (SJS) or toxic
epidermal necrolysis (TEN) and HLA-B*15:02 [6,7],tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and allopurinol-induced SJS or TEN and HLA-B*58:01
[12] have been reported in various populations. For better
understanding of disease causality and drug hypersensitiv-
ity, phase-defined complete HLA gene sequencing is re-
quired. Furthermore, complete HLA gene sequences are
essential to minimize risk of graft versus host disease in
hematopoietic transplantation because unknown determi-
nants could be located around HLA genes.
Two methods of HLA genotyping, sequence specific
oligonucleotide hybridization (SSO) and capillary se-
quencing with chain-termination reaction (Sanger se-
quencing or SBT), have been commonly applied in the
past ten years. SSO requires the preparation of specific
oligonucleotides corresponding to various genotypes in
advance and potential difficulties may arise when new al-
leles are present. SBT or Sanger sequencing simultan-
eously sequences two chromosomes, thereby, phasing of
the highly polymorphic HLA genes is very difficult per
se. The common practice of SBT involves sequencing
exons 2 and 3 of HLA Class I genes and exon 2 of HLA
Class II genes. However, in some cases, different alleles
share similar sequences across the sequenced region,
leading to ambiguity in allele determination. Moreover,
allele determination is generally based on sequence
alignment to the IMGT/HLA database where there is an
inherent limitation.
Rapid progress of sequencing technologies, so called
next generation sequencing (NGS), resulted in revolution-
ary changes in medical genomics by providing massive
sequencing data of human samples. Indeed, the 1,000 ge-
nomes project already reported novel variants including
both rare and common types from population-scale
sequencing [13]. Despite these progresses, complete se-
quence of HLA region could not be provided by the whole
genome analysis because of the extraordinarily poly-
morphic and complex nature of the HLA region. There-
fore, specific analytical procedures should be developed
for completion of HLA sequencing and HLA haplotype
determination. NGS technologies have potential advan-
tages over Sanger method in sequencing HLA genes, i.e.,
sequence of single chromosome can be obtained at high
throughput. Thus far, several high-throughput HLA typ-
ing methods using NGS have been developed [14-17].
One of those involved HLA class I typing by utilizing
the 454 GS FLX Titanium sequencing platform with
barcoding and multiplexing protocol, resulting in a 4-
digit (fields 1 and 2 of HLA allele nomenclature) reso-
lution with high accuracy in HLA-A (95.9%), HLA-B
(99.4%), and HLA-C (94.4%) [16]. Recently, more com-
prehensive analyses of HLA typing using the Illumina
platform were reported to demonstrate accurate geno-
typing via high coverage and extensive sequencing of
the first seven exons of class I genes (HLA-A, -B, and C)and exons 2–5 of class II gene (HLA-DRB1) [17]. Also,
cDNA amplicons of HLA genes were extensively se-
quenced [18,19] and these exon-centric analyses are
successful in determining genotypes after consulting
with the IMGT/HLA database to detect the closest
HLA gene sequence. However, non-coding regions that
may have impact on gene regulation [20,21], or mRNA
splicing [22-24] are ignored. Most recently, 8-digit se-
quencing of HLA-genes is partially achieved using a
combination of long-range PCR and Roche GS Junior
sequencer and/or IonPGM sequencer [25]. In their
study, the closest HLA gene sequence from the IMGT/
HLA database was selected as the reference sequence
for alignment and phasing, and subsequently they could
construct consensus sequence to call HLA alleles. How-
ever, the phasing of single nucleotide variants (SNVs)
separated at distances longer than the sequence reads,
are dependent on the reference sequence because single
read sequences of approximately 500 bp from GS Jr and
260 bp from IonPGM could not clarify phase ambigu-
ities of those SNVs. In addition, if a target sequence is
not registered in the database, it is not feasible to obtain
complete sequences.
In the current study, we completely sequenced long-
range PCR amplicons encompassing entire regions of each
of the following HLA genes (HLA-A, -C, -B, -DRB1, -
DQB1, and -DPB1). PCR amplicons were subjected to
transposase-based library construction and multiplex
sequencing with the MiSeq sequencer. Paired-end reads of
2 × 250 bp enables us to demonstrate phase-defined allele
determination (also defined as HLA gene haplotype) for
33 HLA homozygous samples, 11 HLA heterozygous sam-
ples, and 3 parents-child families.
Results
PCR amplification of the HLA genes and library
preparation
Genomic DNAs from 33 HLA homozygous cell lines, 11
heterozygous individuals, and 3 parents-child families
were PCR amplified and subjected to HLA genes se-
quencing. We applied long-range PCR to amplify six
HLA genes (HLA-A, -C, -B, DRB1, -DQB1, and –DPB1)
that are known to be highly polymorphic. PCR primers
were designed to anneal where known polymorphic sites
were not observed according to the dbSNP build 135
database, and to amplify regions spanning the promoter
to 3′UTR of the HLA genes (Additional file 1: Table
S1). As shown in Additional file 2: Figure S1, specific
amplification products of each gene were obtained; the
PCR amplicon sizes of HLA-A, -C, -B, -DRB1, -DQB1,
and -DPB1 were 3,398 bp, 4,296 bp, 4,440 bp, 11,899 bp,
7,118 bp and 13,605 bp, respectively. Generally allelic
imbalance and allele drop-out as a result of PCR is
manifested by skewed allelic call in next generation
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cation for all the amplicons as judged by the sequencing
results was 1:3.4 at the maximum ratio and 1:1.3 on
average in heterozygous samples (Additional file 3:
Table S2). In addition, extra sequences other than the
target genes were observed. For example, in sequencing
of HLA-A amplicon, sequences of HLA-H were ob-
served as a low frequency extra amplification (<1.85%),
even though we designed PCR primers at the specific
sites of HLA-A and a single amplicon was observed by
the gel electrophoresis. Although the HLA-H reads
might generate false positive SNVs and disturb assembly
results, the reads with low frequency SNVs, which is
most likely regarded as false positive, were removed in
our pipeline during the construction of the HLA gene
haplotype. There is also a possibility that our primers
may have amplified pseudogenes as an invisible amplifi-
cation. However, we constructed only major combina-
tions of SNVs for each specific loci, so minor
amplifications did not disturb the sequencing results.Figure 1 Size selection of the Nextera DNA libraries by agarose gel si
Bioanalyzer. The library size of the Nextera DNA Sample Prep Kits was 150
electropherogram of a selected DNA library by cutting from the agarose g
bp to remove short DNA fragments for effective HLA gene haplotype phas
for bridge PCR to generate clusters in flowcell, because DNA fragments wit
selected fragments was 1,561 bp.All of the PCR amplicons of six HLA genes from an
individual were subjected to transposase-based library
construction using the Nextera DNA Sample Prep Kit,
which simultaneously adds adaptors needed to perform
multiplex sequencing. For a practical reasons, we applied
two different protocols for library preparation: In an
individual-tagging method, all of the PCR amplicons of six
HLA genes from an individual were pooled before being
subjected to transposase treatment; In a gene-tagging
method, each PCR amplicon was subjected to transposase-
based library construction separately, whereby gene specific
index was introduced. The Nextera kit is able to construct
libraries of broad sizes (500 to 2,000 bp) by adding a gel
purification step (Figure 1), and is able to attach indexes for
up to 96 samples as described in the Methods.
Individual-tagging method for complete sequencing of
HLA homozygous samples
The PCR amplicons of the six HLA genes of one indi-
vidual were pooled (the individual-tagging method) andze selection. (A) Electropherogram of DNA library analyzed by 2100
bp to more than 10 kb (mean size: 902 bp). (B) Bioanalyzer
el. We selected large fragments with sizes ranging from 500 to 2,000
ing. The size selection also determines an actual molar concentration
h over 1.5 kb size are not efficiently amplified. The mean size of the
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analyses. Paired-end sequence reads (2 × 250 bp in
length) from 33 HLA homozygous samples, mostly from
established cell lines (Additional file 4: Table S3), were
aligned to the HLA gene sequences of the reference se-
quence (UCSC hg19) allowing 80 bases mismatch in
each 250-base-read derived from the MiSeq sequencer.
Using the above parameters for alignment, on average
66.35% of paired-end reads were able to be aligned to
the reference HLA gene sequence with an average depth
of 157×. The tiling of overlapped paired-end reads
results in a continuous sequence, which should directly
represent the HLA gene haplotype in HLA homozygous
samples (Figure 2A). Paired-end reads from a total of
198 amplicons were obtained (33 individuals; 6 amplicons
per individual). Of those, HLA gene haplotype sequences
could not be generated in 32 amplicons (3 for HLA-A, 2
for -B, 4 for -DPB1, 9 for -DQB1, 14 for -DRB1). This was
due to the presence of long gaps caused by regions with
extremely low depth, which prevented the generation of
continuous gene sequences. All PCR amplicons were
observed as a strong single band by the gel electrophor-
esis. However, the number of sequence reads from 32
amplicons were considerably low. This problem was
caused by a biased amplification during library prepar-
ation of multiple sites using the individual-tagging
method. We analyzed 166 amplicons to generate HLA
gene sequences. Of those, we successfully generated 162
complete sequences which covered the entire span of the
HLA gene (after both ends of amplicons nearby primer
sites were trimmed) without any heterozygous sites. The
remaining 4 sequences covered more than 99.7% of the
entire HLA gene with up to 9 false heterozygous sites
(Table 1). These heterozygous sites were later corrected as
homozygous by an eyeball search using an alignment
viewer and experimentally by the Sanger sequencing.
HLA allele calls for these sequences were obtained by
referring to the IMGT/HLA database, where mostly
complete gene sequences were searched (Table 1). Of the
166 completely homozygous sequences, 152 sequences
were identical to the complete gene sequences recorded in
the IMGT/HLA database. 14 were found to be novel se-
quences, although they are quite similar to the Database
sequences. Most of the novel variants were observed in
the intronic region. Only one novel non-synonymous vari-
ant were detected in DQB1 of sample BM15 (Table 1). Ul-
timately, we could obtain complete sequences without
misalignment for majority of amplicons of the pooled
PCR amplicons by the individual-tagging method for
homozygous samples.
We attempted to apply the individual-tagging method
to the 11 HLA heterozygous samples. However, we
could not obtain phase-defined sequences, probably due
to mismapping of paired-end reads, as evidenced by thehigh detection rate of the variants. Therefore, we applied
the gene-tagging method for HLA heterozygous samples.
Gene-tagging method for complete sequencing of HLA
heterozygous samples
For HLA heterozygous samples, each PCR amplicon was
separately subjected to the transposase-based library
construction for sequencing as the gene-tagging method.
We successfully obtained sequences of 6 genes in 11 HLA
heterozygous individuals, resulting in a total of 66
amplicons. Paired-end reads (2 × 250 bp) from an amplicon
were aligned to the respective HLA gene of the hg19 refer-
ence, allowing maximum 80 mismatches per read. On
average, 73.1% of all reads could be successfully mapped to
the reference sequence for all 66 amplicons. Overall, the
average depth for the 66 amplicons ranged from 146× to
6,678×, with a mean of 2,281× (Table 2). In general, HLA
class I genes tend to have higher average coverage (3,405×)
compared to HLA class II genes (1,157×), which may be
due to the larger amplicon sizes for HLA class II genes.
First, we tried to detect informative paired-end reads
harboring SNVs on both forward and reverse reads; this
information is used to separate two chromosomes and
to determine the two phase-defined HLA gene se-
quences. Taking advantage of highly polymorphic nature
of the HLA genes, wide-ranged library size, and deep se-
quencing, it becomes possible to phase sequence reads
on a chromosome and tile phased reads to generate
HLA gene haplotype sequences (Figure 2B). After align-
ment to the respective HLA gene reference sequence
(hg19), two HLA gene haplotype sequences based on
phase-defined SNVs were generated (Figure 2B). Overall,
we were able to obtain 132 phase-defined sequences (66
amplicons; 2 chromosomes each). Of those, we success-
fully generated 103 complete haploid sequences which
covered the entire span of the HLA gene (after both
ends of amplicons nearby primer sites were trimmed).
The remaining 26 haploid sequences covered more than
95% of the entire HLA gene whereas another three had
less than 95% coverage (Table 2). The incomplete cover-
age of the HLA genes was due to remaining unphased
regions, which may include large gaps. Most notably,
our phase-defined sequencing does not refer to the
IMGT/HLA database in order to generate HLA gene
sequences unlike HLA typing methods using NGSs
reported thus far.
After obtaining phase-defined HLA gene sequences
for 132 haploid sequences, we tried to designate HLA al-
lele numbers to these sequences by searching for known
allele sequences in the IMGT/HLA database. First, we
used the phased HLA gene haplotype sequences that
spanned all of the intronic and exonic regions of the
HLA gene, as a query against complete gene sequences
in the database. Because sequencing efforts of the HLA
Figure 2 Schematic workflow of the phase-defined HLA gene sequencing. (A) The individual tagging method for HLA homozygous
samples. The 2 × 250 bp paired-end reads of the pooled amplicons were aligned to six HLA gene sequences from the hg19 and the consensus
sequences were determined. Most of the analytical tools shown here are standard use for genome sequence alignment and variant detection.
For generating consensus sequence, we used original perl scripts to list variants and to construct HLA gene sequences. (B) The gene-tagging
method for HLA heterozygous samples. The 2 × 250 bp paired-end reads of the each amplicon were aligned to the corresponding gene and six
genes were separately analyzed to avoid mismapping. In the alignment step, 2 × 250 bp paired-end sequence reads were aligned to reference
sequence using BWA and SAMtools. SNVs were detected by UnifiedGenotyper in GATK. Paired-end reads harboring SNVs in both forward and
reverse reads were extracted to construct two phased HLA gene haplotype sequences using our original perl script. Finally, two HLA gene
haplotype sequences from an individual were generated with phase-defined SNVs and Indels as HLA gene haplotypes.
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available complete gene sequences in the database tend
to be lacking compared to coding region sequences. If
we did not get any hit in the complete HLA gene se-
quence database, we extracted exon sequences from our
complete, phased HLA gene haplotype sequences to ob-
tain HLA coding sequences and searched them for
known cDNA sequences in the database. Overall, wewere able to determine the closest HLA allele number
for all of our HLA gene haplotype sequences by
searching for the database (Table 2). Of those, 104 alleles
were obtained by searching for the complete gene se-
quences and another 28 obtained by searching the
cDNA database. We managed to obtain perfect match
with the database in 100 HLA gene haplotypes of the
heterozygous samples, resulting in 6 to 8 digit HLA
Table 1 Alignment result of the HLA gene sequence and genotype in the HLA homozygous cell lines







AKIBA A 24:02 219.5 0 100 A*24:02:01:01
C 12:02:02 655.5 0 100 C*12:02:02
B 52:01 74.0 0 100 B*52:01:01:02
DRB1 15:02 346.9 0 100 DRB1*15:02:01
DQB1 06:01:01 33.2 0 100 DQB1*06:01:01
DPB1 09:01 604.9 0 100 DPB1*09:01
AMAI A 68:02 35.2 0 100 A*68:02:01:01
C 04:01 159.3 0 100 C*04:01:01:01
B 53:01 52.2 0 100 B*53:01:01
DRB1 15:03 92.6 0 100 DRB1*15:03:01 2bp (TG) deletion
DQB1 06:02 133.6 0 100 DQB1*06:02:01
DPB1 04:02 94.9 0 100 DPB1*105:01 different from ECACC
ARBO A 03:01 133.5 0 100 A*03:01:01:01
C 06:02 208.8 0 100 C*06:02:02:01
B 58:02 108.2 0 100 B*58:02
DRB1 15:03 43.4 - 86.6 not determined
DQB1 06:02 40.0 - 71.5 not determined
DPB1 04:02 100.6 0 99.2 not determined
BM15 A 01:01 79.3 0 100 A*01:01:01:01
C 07:01 198.7 0 100 C*07:01:01
B 49:01 34.0 0 100 B*49:01:01
DRB1 11:02 90.9 0 98.3 not determined
DQB1 03:01 14.2 0 100 DQB1*03:01:01:01 2 intronic and 1 nonsynonymous
novel variants
DPB1 03:01 132.0 0 100 DPB1*03:01:01 24 intronic novel variants
BM16 A 02:01 28.6 0 100 A*02:01:01:01
C 07:01 249.0 0 100 C*07:01:01:01
B 18:01 183.3 0 100 B*18:01:01 3 intronic novel variants
DRB1 12:01 55.4 0 100 DRB1*12:01:01 43 intronic novel variants
DQB1 03:01 36.3 0 100 DQB1*03:01:01:01 1 intronic novel variant
DPB1 02:01:02 58.3 0 100 DPB1*02:01:02 4bp (GGAA) insertion
BM21 A 01:01 61.0 0 100 A*01:01:01:01
C 17:01 233.0 0 100 C*17:01:01:02
B 41:01 176.3 0 100 B*41:01
DRB1 11:01 80.0 0 100 DRB1*11:01:01
DQB1 03:01 17.8 9† 99.7 DQB1*03:01:01:01
DPB1 10:01 103.8 0 100 DPB1*10:01
BM92 A 25:01:01 24.1 0 100 A*25:01:01
C 01:02 458.0 0 100 C*01:02:01
B 51:01:01 218.0 0 100 B*51:01:01
DRB1 04:04 2.9 - 32.9 not determined
DQB1 03:01 1.1 - 0 not determined
DPB1 04:02 115.6 0 100 DPB1*04:02:01
Boleth A 02:01:01:01 25.7 1† 100 A*02:01:01:01
C 03:04 273.3 0 100 C*03:04:01:01
B 15:01 260.2 0 100 B*15:01:01:01
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Table 1 Alignment result of the HLA gene sequence and genotype in the HLA homozygous cell lines (Continued)
DRB1 04:01:01 27.1 0 98.4 not determined
DQB1 03:02:01 67.2 0 100 DQB1*03:02:01
DPB1 04:01:01 99.1 0 100 DPB1*04:01:01
BSM A 02:01 56.9 0 100 A*02:01:01:01
C 03:04 238.6 0 100 C*03:04:01:01
B 15:01 204.3 0 100 B*15:01:01:01
DRB1 04:01 18.3 0 98.4 not determined
DQB1 03:02 91.1 0 100 DQB1*03:02:01
DPB1 02:01:02 57.6 0 100 DPB1*02:01:02
Carogero A 02:01 28.2 0 100 A*02:01:01:01
C 20:22 22.8 0 100 C*02:02:02
B 40:02 6.1 - 91 not determined
DRB1 - 16.8 0 100 DRB1*16:01:02
DQB1 - 27.5 0 100 DQB1*05:02:01
DPB1 04:01 18.8 0 99.7 not determined
COX A 01:01:01:01 99.1 0 100 A*01:01:01:01
C 07:01:01 322.2 0 100 C*07:01:01
B 08:01:01 123.5 0 100 B*08:01:01
DRB1 03:01 284.9 0 100 DRB1*03:01:01
DQB1 02:01 367.3 0 100 DQB1*02:01:01
DPB1 03:01 270.5 0 100 DPB1*03:01:01
DBB A 02:01 454.2 0 100 A*02:01:01
C 06:02 636.8 0 100 C*06:02:01:01
B 57:01 142.5 0 100 B*57:01:01
DRB1 07:01 14.3 - 90.7 not determined
DQB1 30:32 1.9 - 70.8 not determined
DPB1 04:01 568.0 0 100 DPB1*04:01:01:01
DHI A 31:01 2.2 - 12.9 not determined
C 12:03 292.9 0 100 C*12:03:01:01
B 38:01 250.1 0 100 B*38:01:01
DRB1 11:01 57.2 0 100 DRB1*11:01:01
DQB1 03:01 140.1 0 100 DQB1*03:01:01:03
DPB1 04:01 302.2 0 100 DPB1*04:01:01:01
DKB A 24:02 358.6 0 100 A*24:02:01 1 intronic novel variant
C 03:04 502.8 0 100 C*03:04:01:01
B 40:01 634.1 0 100 B*40:01:02
DRB1 90:12 61.4 - 65 not determined
DQB1 30:32 310.1 0 100 DQB1*03:03:02:02
DPB1 04:01 259.2 0 100 DPB1*04:01:01:01
HARA A 24:02:01:01 122.6 0 100 A*30:01:01 different from ECACC
C 12:02 214.3 0 100 C*12:02:02
B 52:01:01 189.1 0 100 B*52:01:01:02
DRB1 15:02:01 4.5 0 97.5 not determined
DQB1 06:01 124.6 0 100 DQB1*06:01:01
DPB1 09:01 52.9 - 97.6 not determined
HHK A 03:01 265.9 0 100 A*03:01:01:01
C 07:02 84.6 0 100 C*07:02:01:03
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Table 1 Alignment result of the HLA gene sequence and genotype in the HLA homozygous cell lines (Continued)
B 07:02 11.5 0 100 B*07:02:01
DRB1 13:01 47.7 0 100 DRB1*13:01:01
DQB1 06:03 103.3 0 100 DQB1*06:03:01
DPB1 04:01 65.1 0 100 DPB1*04:01:01:01
HOKKAIDO A - 8.0 0 100 A*24:02:01:01
C - 42.8 0 100 C*03:04:01:02
B - 99.0 0 100 B*54:01:01
DRB1 04:05 8.2 - 11.6 not determined
DQB1 04:01 48.4 - 57.4 not determined
DPB1 05:01 70.4 0 100 DPB1*05:01:01
JBUSH A 32:01 10.9 1† 100 A*32:01:01
C 12:03 128.8 0 100 C*12:03:01:01
B 38:01 298.3 0 100 B*38:01:01
DRB1 11:01 23.7 0 100 DRB1*11:01:03
DQB1 03:01 80.1 0 100 DQB1*03:01:01
DPB1 04:01 86.7 0 100 DPB1*04:01:01:01
JEST A 02:01 11.3 0 100 A*02:01:01
C 01:02 80.3 0 100 C*01:02:01
B 27:05:02 76.8 0 100 B*27:05:02 1 intronic novel variant
DRB1 01:01 16.3 0 100 DRB1*01:01:01
DQB1 05:01 87.5 0 100 DQB1*05:01:01 1 intronic novel variant
DPB1 04:01 69.1 0 100 DPB1*04:01:01:01
K265 A - 127.1 0 100 A*03:01:01:01
C 12:02 163.7 0 100 C*07:02:01:03
B - 54.3 0 100 B*07:02:01
DRB1 15:02 92.7 0 100 DRB1*15:01:01
DQB1 - 257.5 0 100 DQB1*06:02:01
DPB1 - 107.8 0 100 DPB1*04:01:01:01
LBUF A 30:01:01 26.9 0 100 A*30:01:01
C 06:02 326.3 0 100 C*06:02:01:01
B 13:02:01 249.1 0 100 B*13:02:01
DRB1 07:01:01 16.6 0 100 DRB1*07:01:02
DQB1 02:02 2.9 - 18.9 not determined
DPB1 17:01 177.9 0 100 DPB1*17:01
LKT3 A 24:02 86.9 0 100 A*24:02:01
C 01:02 213.3 0 100 C*01:02:01
B 54:01 48.7 0 100 B*54:01:01
DRB1 08:01 23.4 - 55.4 not determined
DQB1 04:01 1.1 - 0 not determined
DPB1 05:01 227.8 0 100 DPB1*05:01:01
MADULA A 02:01 86.8 0 100 A*02:01:01
C 03:04 206.9 0 100 C*03:04:01
B 40:01 223.8 0 100 B*40:01:02
DRB1 08:01 42.6 0 100 DRB1*08:01:03
DQB1 04:02 123.9 - 86.3 not determined
DPB1 04:01 215.6 0 100 DPB1*04:01:01
PITOUT A 29:02 91.5 0 100 A*29:02:01
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Table 1 Alignment result of the HLA gene sequence and genotype in the HLA homozygous cell lines (Continued)
C 16:01 51.8 0 100 C*16:01:01
B 44:03:01 74.6 0 99.4 not determined
DRB1 07:01 3.2 40.4 not determined
DQB1 02:01 38.3 0 100 DQB1*02:02 different from ECACC
DPB1 04:01 340.7 0 100 DPB1*04:01:01
RMAL A 02:04 75.8 0 100 A*02:04
C 15:02 68.6 0 100 C*15:02:01
B 51:01 21.9 0 100 B*51:01:01
DRB1 16:02 63.5 0 100 DRB1*16:02:02 3 intronic novel variants
DQB1 03:01 16.2 0 100 DQB1*03:01:01
DPB1 04:02 66.8 0 100 DPB1*04:02:01
SAVC A 03:01 99.4 0 100 A*03:01:01:01
C 07:02 140.3 0 100 C*07:02:01
B 07:02 45.3 0 100 B*07:02:01
DRB1 04:01 2.4 - 50.3 not determined
DQB1 03:02 1.2 - 12.9 not determined
DPB1 10:01 129.2 0 100 DPB1*10:01
SRACH A 31:01 14.5 - 1.5 not determined
C 01:02 388.3 0 100 C*01:02:01
B 15:01 688.5 0 100 B*15:01:0101
DRB1 08:02:01 61.5 0 100 DRB1*08:02:01
DQB1 04:02 174.0 - 91 not determined
DPB1 04:02 207.0 0 100 DPB1*04:02:01
T182 A 24:02 12.4 0 100 A*24:02:01:01
C 12:02:02 113.5 0 100 C*12:02:02
B 52:01 106.0 0 100 B*52:01:01:02
DRB1 15:02 4.9 - 0 not determined
DQB1 06:01 72.2 0 100 DQB1*06:01:01
DPB1 09:01 69.2 0 98.3 not determined
TAB089 A 02:07 13.3 0 98.3 not determined
C 01:02 101.9 0 100 C*01:02:01
B 46:01 36.9 0 100 B*46:01:01
DRB1 02:02 2.7 - 91.1 not determined
DQB1 06:01 49.1 1† 100 DQB1*06:01:01
DPB1 02:02 39.2 0 100 DPB1*02:02 9 intronic novel variants
TOK A 24:02 286.2 0 100 A*24:02:01:01
C 12:02:02 241.5 0 100 C*12:02:02
B 52:01 127.9 0 100 B*52:01:01:02
DRB1 15:02 163.7 0 100 DRB1*15:02:01
DQB1 06:01 243.1 0 100 DQB1*06:01:01
DPB1 09:01 175.2 0 100 DPB1*09:01
VAVY A 01:01 36.1 0 100 A*01:01:01:01
C 07:01 141.6 0 100 C*07:01:01
B 08:01 535.1 0 100 B*08:01:01
DRB1 03:01 43.4 0 100 DRB1*03:01:01
DQB1 02:01 126.4 0 100 DQB1*02:01:01:01
DPB1 01:01 57.0 0 100 DPB1*01:01:01
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Table 1 Alignment result of the HLA gene sequence and genotype in the HLA homozygous cell lines (Continued)
WT100 A 11:01 66.4 0 100 A*11:01:01
C 04:01 112.9 0 100 C*04:01:01:02
B 35:01 15.9 0 100 B*35:01:01
DRB1 01:01 143.5 0 100 DRB1*01:01:01
DQB1 05:01 136.4 0 100 DQB1*05:01:01 1 intronic novel variant
DPB1 01:01 122.0 0 100 DPB1*01:01:01
WT47 A 32:01 56.5 0 100 A*32:01:01
C 05:01 192.5 0 100 C*05:01:01
B 44:02 47.8 0 100 B*44:02:01
DRB1 13:02 116.1 0 100 DRB1*13:02:01 4 intronic novel variants
DQB1 06:04 807.8 0 100 DQB1*06:04:01
DPB1 16:01 172.2 0 100 DPB1*16:01
* Percentage of the HLA gene covered by reads that passed the Q20 threshold for nucleotide quality.
† Confirmed by sanger sequence.
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recorded 1 to 5 bp mismatches with known sequences
in the database, where 17 HLA gene haplotypes had
mismatches in the exonic region and 15 HLA gene hap-
lotypes had mismatches in the intronic region. These
mismatches may be due to new alleles, reflecting defi-
ciencies of the database, or be due to our sequencing
error. In conclusion, we could successfully determine
the HLA allele numbers for all of HLA sequences.
Parent/child trios for the confirmation of the HLA gene
sequences
Phase-defined HLA gene haplotype structure is classic-
ally confirmed by the cloning and Sanger sequencing
method, because it is not feasible to define the phase by
using the Sanger sequencing only. Because the cloning
and sequencing method is laborious, inefficient, and im-
practical for sequencing massive samples, we took a gen-
etic approach applying parents/child trios to define the
phase of the gene sequences and also to confirm the fi-
delity of our results. Individuals from three trio (parents
and child pair) families were all subjected to the HLA
gene sequencing protocol as previously described using
the gene-tagging method. All the phase-defined sequen-
cing data of the HLA genes were consistent with the
SSO genotyping data (data not shown) and the heredi-
tary pattern confirming the validity of our phase-defined
sequencing and analytical pipeline (Figure 3). HLA gene
haplotype structure is inferred by the family structure
and recombination event in three trio families was not
observed.
Discussion
The primary goal of our current study is to determine
phase-defined complete HLA-gene sequencing without
ambiguity. The six highly polymorphic HLA genes (HLA-
A, -C, -B, -DRB1, -DQB1, and -DPB1) were amplified bylong-range PCR and the PCR amplicons covering full se-
quences of the genes were subjected to the MiSeq sequen-
cer via the transposase-based library preparation. The
derived paired-end reads (2 × 250 bp) from the MiSeq se-
quencer were analyzed by the one step alignments to the
UCSC hg19 to obtain phase-defined complete sequences.
Thus far, several methods to sequence HLA genes with
next generation sequencers were reported. These methods
are based on PCR-amplification of specific regions of
HLA genes followed by NGS, mostly using the 454 GS
FLX Titanium sequencing platform [14-16]. Derived se-
quence reads were usually mapped to a reference library
of HLA gene sequences such as the IMGT-HLA database
in the alignment step. Then, the closest sequences are se-
lected as the reference sequences for alignment. Because
only a limited number of full sequences of the HLA genes
is registered in the database, derived complete gene se-
quences are hardly mapped. Accordingly, most studies
only map exon sequences on cDNA references from the
IMGT-HLA database. For example, because exons 2 and
3 of class I genes and exon 2 of class II genes are highly
polymorphic and critical for antigen presentation, several
studies practically focused on sequencing these exons
[14,16]. Recent publications showed more extensive se-
quencing targeting all exons by PCR or cDNA amplifica-
tion demonstrating complete sequencing of the coding
regions [18,19]. If exons are separately sequenced, phased
HLA gene sequence (or HLA gene haplotype) can not be
defined, indeed, the HLA gene haplotype was inferred by
the IMGT-HLA database. The complete cDNA sequen-
cing can automatically define the HLA gene haplotype
structures of the exons without inference [18,19], however,
preparation of cDNA is not practical, especially consider-
ing the clinical application. The exon-centric analyses are
efficient in data-analyses, however, two fundamental
shortcomings need to be reminded: First, it has been
reported that expression level of HLA genes is associated
Table 2 Sequence quality and closest HLA allele designation for heterozygous samples
Sample Gene Average depth Coverage¶ (allele 1/allele 2) Luminex genotype Closest HLA genotype
E1 A 4306.6 97.1/100 02:01/31:01 02:01:01:01/31:01:02
C 6668.5 100/99.6 03:03/03:04 03:03:01/03:04:01:01
B 5250.9 100/100 15:11/40:01 15:11:01*/40:01:02
DRB1 272.2 99.7/95.6 04:05/09:01 04:05:01/09:01:02*
DQB1 3322.3 100/99.5 03:03/04:01 03:03:02:02/04:01:01
DPB1 780.8 95.5/100 02:02/05:01 02:02/05:01:01*
E8 A 4303.7 100† 24:02/24:02 24:02:01:01/24:02:01:01
C 3904.7 100/100 12:02/14:02 12:02:02/14:02:01
B 2829.4 99.7/100 51:01/52:01 51:01:01/52:01:01:01
DRB1 612.3 100/100 01:01/15:02 01:01:01/15:02:01
DQB1 3132.6 100/100 05:01/06:01 05:01:01:02/06:01:01
DPB1 588.7 100/100 04:02/09:01 04:02:01:02/09:01
E11 A 3880.2 100/100 24:02/31:01 24:02:01:01/31:01:02
C 3695.0 100/100 01:02/07:04 01:02:01/07:04:01
B 4490.7 100/100 15:18/54:01 15:18:01*/54:01:01
DRB1 501.8 78.3/99.2 04:01/04:05 04:01:01/04:05:01
DQB1 3751.8 100/100 03:01/04:01 03:01:01:01/04:01:01*
DPB1 748.2 100/100 02:01/05:01 02:01:02*/05:01:01*
E17 A 808.4 100/100 02:07/24:02 02:07:01/24:02:01:01
C 1708.7 100/100 01:02/12:02 01:02:01/12:02:02
B 2507.7 100/100 46:01/52:01 46:01:01/52:01:01:02
DRB1 2080.3 100/100 08:03/15:02 08:03:02/15:02:01
DQB1 1638.1 100† 06:01/06:01 06:01:01/06:01:01
DPB1 1649.6 97.9/98.4 05:01/09:01 05:01:01*/09:01
E25 A 1042.7 100/100 02:06/24:02 02:06:01/24:02:01:01
C 2150.0 100/100 07:02/12:02 07:02:01:03/12:02:02
B 4871.7 100/100 07:02/52:01 07:02:01/52:01:01:02
DRB1 460.3 100/32.8 01:01/09:01 01:01:01*/09:01:02*
DQB1 1396.3 100/100 03:03/05:01 03:03:02:02/05:01:01:02*
DPB1 2289.0 99.6/100 02:02/04:02 02:02*/04:02:01:01*
E28 A 1645.3 97.2/100 26:01/33:03 26:01:01/33:03:01*
C 824.8 99.7† 03:04/03:04 03:04:01:02/03:04:01:02
B 2799.6 100/100 40:02/40:06 40:02:01*/40:06:01:01
DRB1 236.5 100† 09:01/09:01 09:01:02*/09:01:02*
DQB1 817.5 100† 03:03/03:03 03:03:02:02/03:03:02:02
DPB1 343.0 100† 02:01/02:01 02:01:02/02:01:02
E30 A 1711.4 100/100 24:02/33:03 24:02:01:01/33:03:01*
C 2670.8 100/100 01:02/14:03 01:02:01*/14:03
B 1899.1 100/100 44:03/55:02 44:03:01/55:02:01
DRB1 399.4 17.1/99.8 09:01/13:02 09:01:02*/13:02:01*
DQB1 773.1 100/97.8 03:03/06:04 03:03:02:02/06:09*
DPB1 460.4 100/100 04:01/04:01 04:01:01/04:01:01
M13 A 3689.7 97.2/100 11:01/24:02 11:01:01/24:02:01:01
C 3386.3 100/100 01:02/04:01 01:02:01/04:01:01:01
B 3508.5 100/100 15:01/59:01 15:01:01:01/59:01:01:01
DRB1 1029.3 100/99.5 04:05/09:01 04:05:01/09:01:02*
DQB1 577.6 100/100 03:03/04:01 03:03:02:02/4:01:01
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Table 2 Sequence quality and closest HLA allele designation for heterozygous samples (Continued)
DPB1 1981.8 100/100 04:02/05:01 04:02:01:02/05:01:01*
M14 A 1690.3 100/100 31:01/33:03 31:01:02/33:03:01
C 4353.2 100/100 04:01/06:02 04:01:01:01/06:02:01:01
B 4733.5 100/100 15:01/57:01 15:01:01:01/57:01:01
DRB1 446.2 100/99.5 15:01/07:01 15:01:01:02*/07:01:01
DQB1 763.0 98.8/98.9 03:03/06:02 03:03:02:01/06:02:01
DPB1 1209.5 99.8/100 09:01/04:02 09:01/04:02:01:02*
M15 A 1153.2 100/100 31:01/33:03 31:01:02/33:03:01
C 1448.1 99.7/99.8 14:02/14:03 14:02:01/14:03
B 3312.9 100/100 44:03/51:01 44:03:01/51:01:01
DRB1 463.4 100† 04:05/04:05 04:05:01/04:05:01
DQB1 280.9 100† 04:01/04:01 04:01:01*/04:01:01*
DPB1 2932.9 99.5/100 02:01/03:01 02:01:02/03:01:01
M20 A 7631.1 100/100 02:06/11:01 02:06:01/11:01:01
C 7675.7 100/100 03:03/08:01 03:03:01/08:01:01
B 7566.7 100/100 15:02/35:01 15:02:01/35:01:01:01*
DRB1 4746.2 100† 15:01/15:01 15:01:01:01/15:01:01:01
DQB1 6952.9 100/100 06:01/06:02 06:01:01/06:02:01
DPB1 4631.3 100/99.6 05:01/02:02 05:01:02/02:02
¶ Percentage of the HLA gene covered by reads that passed the Q20 threshold for nucleotide quality.
*Mismatched bases with recorded sequences in IMGT/HLA database observed.
† Homozygous HLA allele.
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regulatory element such as promoter or even introns need
to be extensively analyzed. In fact, a variant of intron 2 of
HLA-A was reported as causality of low expression of the
HLA gene, furthermore, variants in intron 2 of HLA-A, in-
trons 2 and 4 of HLA-B cause null expression by cryptic
splicing activation [22-24]. Thus, promoter/enhancer, in-
tron, and 3′-UTR variants should not be ignored for com-
prehensive HLA typing. Second, because of high linkage
disequilibrium in the HLA region, true causalities of dis-
eases and drug adverse effects including regulatory vari-
ants can not be identified unless phase-defined complete
gene sequence and HLA haplotype structure are achieved.
Because of that, Shiina et al. established the sequence-
based typing method for the 8 HLA genes (HLA-A, -B, -C,
-DRB1, -DQA1, -DQB1, -DPA1, and -DPB1) sequencing
up to 8-digit resolution [25]. But their protocol basically
relies on the IMGT-HLA database and HLA gene haplo-
type determination is based on inference, thus phase-
defined HLA gene haplotype structure of novel sequence
could hardly be achieved.
We report here an analytical pipeline for determining
phase-defined complete sequencing of the six HLA
genes. The long-range PCR products of HLA genes
spanning from promoter to 3′-UTRs were prepared and
sequenced by the MiSeq sequencer via the transposase-
based library preparation. We applied only one referencesequence, UCSC hg19, for alignment, which not only
simplifies the analytical step but also can accommodate
all the samples. This is the major advantage using the
proposed protocol because novel allele could be deter-
mined by our sequencing pipeline. Also we prepared a
large and broad sized library (500–2,000 bp) using the
Nextera kit, which can generate paired-end reads of a
variety of sizes (Figure 1), which facilitates our phase-
defined sequencing method. Overall, we determined 162
HLA gene haplotype sequences from homozygous cell
lines, 132 HLA gene haplotype sequences from hetero-
zygous samples and 60 HLA gene haplotype sequences
from trio/quartet from 3 families. We applied two differ-
ent procedures to prepare DNA library for MiSeq sequen-
cing; the individual-tagging and gene-tagging methods.
The Nextera DNA Sample Preparation Kit enables tagging
of up to 96 libraries with unique dual indexes, which are
added via PCR primers during the final amplification step.
In the individual-tagging method, 576 amplicons derived
from 6 HLA genes of 96 samples can be analyzed in one
run, whereas 96 amplicons are analyzed using the gene-
tagging method. We are aware that the current protocol
for HLA heterozygous samples with the gene-tagging
method would be low throughput and costly compared
with the individual-tagging method, although providing
accurate genotyping. Evidently, there is much room to be
improved. We are in a stage to develop a new mapping
Figure 3 The HLA alleles and HLA haplotypes in two trio (A and C) one quartet (B) families. Each individual in child-parents families was
sequenced as described. Each HLA gene call was consistent with the hereditary pattern. HLA allele was inferred by the IMG/HLA database and
shared between parents and child(ren) with consistent pattern and without recombination.
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zygous samples by the individual-tagging method.Conclusions
We established the high throughput, high resolution,
and high fidelity HLA genotyping using transposase-
based library construction and multiplex sequencing
with MiSeq sequencer. Using the transposase-based
library preparation method, it becomes feasible to con-
struct multi-libraries (up to 96 libraries) with dual index
at once for only 90 minutes. These could be greatly
advantageous for clinical (diagnostic) application thatrequires a user-friendly and cost-effective protocol, with
high throughput and accuracy. In conclusion, we are
able to determine the phase-defined entire HLA gene se-
quences, regardless whether the alleles are rare or novel.Methods
DNA samples
Genomic DNA of 33 HLA homozygous cell lines from
15 countries (Additional file 4: Table S3), 11 healthy
participants and three families of parents/child trios or
quartet were applied. All subjects gave written informed
consent for genetic screening. Ethical approvals for this
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tees of National Institute of Genetics and Tokai Univer-
sity School of Medicine.
HLA genotyping with PCR-SSO method
We genotyped HLA-A, HLA-C, HLA-B, HLA-DRB1,
HLA-DQB1, and HLA-DPB1 using the Luminex assay
system and HLA typing kits (WAKFlow HLA Typing
kits, Wakunaga, Osaka, Japan or LABType SSO, One
Lambda, Canoga Park, CA).
Sequencing of HLA genes
The six HLA genes (HLA-A, -C, -B, -DRB1, -DQB1, and
-DPB1) were each amplified using locus specific primers
(Additional file 1: Table S1) with a long-range PCR
method. The primers were designed to anneal to con-
served regions, i.e., having no recorded variants in
dbSNP135. Each amplification reaction contained 20 ng of
genomic DNA, 0.25 unit of PrimeSTAR® GXL DNA poly-
merase (TAKARA BIO INC., Japan), 1× PrimeSTAR®
GXL buffer (Mg2+ concentration 1 mM), 0.2 mM of each
dNTP, and 0.2 μM of each primer in a 10 μl reaction vol-
ume. Cycling parameters were as follows: initial denatur-
ation of 94°C/2 min followed by 30 cycles of 98°C/10 sec,
60°C/15 sec and 68°C/10 min. DNA libraries of these PCR
products were prepared by a transposase-mediated library
preparation method with the Nextera DNA Sample Prep-
aration Kit (Illumina, San Diego, CA, USA) allowing re-
duced amount of DNA (50 ng) and time for the library
construction (90 min). Briefly, PCR product was treated
with the Tn5 transposase artificially loaded with synthetic
oligonucleotides, enabling simultaneous fragmentation
and addition of an adaptor. Each sample was dual indexed
and equally pooled by evaluating the molar concentration
by Agilent High Sensitivity DNA Kit and 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA). Fragments
ranging from 500 to 2,000 bp (mean size: 1,561 bp), were
selected from the pooled library by adding size fraction-
ation step from agarose gel (Figure 1). The library was
subjected to multiplex sequencing on the MiSeq se-
quencer (Illumina). The MiSeq flowcell of 2 × 250 bp
paired-end reads resulted in 15 to 17 million read pairs
corresponding to 5.8 to 8.5 billion bases of sequence data.
The average depths were 157× for homozygous samples
with the individual-tagging method and 2,281× for hetero-
zygous samples with the gene-tagging method, respect-
ively. All sequence data associated with this project has
been submitted to DDBJ Sequence Reads Archive (DRA
accession number DRA000908) and compiled in National
Bioscience Database Center (http://biosciencedbc.jp/en/).
Determination of HLA gene sequences
Sequence reads were distributed according to each index
information to assign individuals. Adapter sequence andlow quality bases (Phred quality score <Q30) were then
excluded and only long (> 200 bp) paired-end reads were
selected. These qualified sequence reads were aligned to
the 6 HLA gene sequences of UCSC hg19 reference using
the BWA (Version 0.5.17; http://bio-bwa.sourceforge.net/)
[26] and SAMtools (Version 0.1.18; http://samtools.
sourceforge.net/) [27] After the paired-end reads were
aligned, SNVs were identified using UnifiedGenotyper in
GATK package (http://www.broadinstitute.org/gsa/wiki/
index.php/Home_Page) [28,29] and our original perl script
to remove false positive SNVs based on the proportion of
variant reads to total reads at each SNV site.
In the individual-tagging method for HLA homozy-
gous samples, paired-end reads of the selected size from
pooled amplicons were simultaneously aligned to six
HLA genes of the hg19 reference sequence, and then six
consensus sequences based on the defined SNVs and
Indels were obtained. In the gene-tagging method for
HLA heterozygous samples, paired-end reads from one
amplicon of the HLA gene were aligned to the corre-
sponding HLA gene reference of UCSC hg19 reference,
and SNVs and Indels were detected using the same
pipeline in the individual-tagging method. Heterozygous
SNVs were utilized for HLA gene haplotype phasing.
More specifically, paired-end reads showing SNVs in
both forward and reverse reads were extracted from the
alignment result, and the paired-end reads having het-
erozygous SNV sites were tiled to generate two HLA
gene haplotypes using our original perl script. The script
extracts only heterozygous bases from SAM file, and
tabulates read-backed HLA gene haplotypes from paired-
end reads, and finally tiles subset of HLA gene haplotype
to construct complete phased SNVs as HLA gene haplo-
types (Figure 2). The two HLA gene haplotype alignments
were reconstructed by these phased SNV information
from SAM file, and continuous sequences having high
consensus quality score (> Q20) [27] were created and
searched for databases.
Search for database and HLA allele determination
The phase-defined HLA gene sequences were subjected
to HLA allele determination by searching the IMGT/
HLA (http://www.ebi.ac.uk/imgt/hla/) database. Using
our method, we were able to obtain complete gene se-
quences of six HLA genes and it is possible to use those
complete gene sequences when searching against the
database. However, because most of the sequences in
database are only for coding region, we extracted exon
sequences and merged them to construct a coding se-
quence. We then used them as query when doing a
BLAT [30] search against known HLA allele sequences
in the database, allowing for up to 1% mismatch. The
pipeline to construct phased HLA gene sequences, and
call HLA alleles up to 8 digit are available in p-galaxy in
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reads fastq files are required to generate phased HLA
gene sequence and determine the allele number.
Additional files
Additional file 1: Table S1. PCR primers and estimated amplicon size
for the 6 HLA genes.
Additional file 2: Figure S1. PCR amplification of the six HLA genes.
(A) Amplified region of the six loci, where dark green boxes represent
exons. Red arrows indicate the amplified region. (B) Agarose gel
electrophoresis of PCR products and sizes of each amplicon.
Additional file 3: Table S2. The average frequency of minor allele as
an indicator of allelic imbalance in heterozygous samples.
Additional file 4: Table S3. The HLA homozygous cell lines and
genotype of the HLA loci.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KH and II designed the research and participated in manuscript preparation.
KH TAJ and HN developed the bioinformatics method. MS performed HLA
typing using SSO method. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported by the Grant-in-Aid for Scientific Research on
Innovative Areas (22133002), and “Genome Science” (No.221S0002) from
Ministry of Education, Culture, Sports, Science and Technology of Japan (K.H,
I.I, H.N) and Takeda Science Foundation (K.H). We are grateful to Dr. Takashi
Shiina, Dr. Hidetoshi Inoko, Department of Molecular Life Sciences, Tokai
University School of Medicine for their excellent advice, Mr. Masayuki Tanaka,
the Education and Research Support Center, Research and Development
Division, Isehara, Tokai University for his both routine and specialized
laboratory and in silico works, Dr. Atsushi Toyoda, Center for Information
Biology, Comparative Genomics Laboratory, National Institute of Genetics, for
making sequence data. We express our deepest gratitude, to Ms. Ayako
Otake, Mr. Ryota Sugimoto and Ms. Junko Kajiwara for their technical
assistances.
Author details
1Division of Human Genetics, National Institute of Genetics, 1111 Yata,
Mishima, Shizuoka 411-8540, Japan. 2Department of Molecular Life Sciences,
Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa
259-1143, Japan.
Received: 15 January 2013 Accepted: 20 May 2013
Published: 28 May 2013
References
1. Shiina T, Hosomichi K, Inoko H, Kulski JK: The HLA genomic loci map:
expression, interaction, diversity and disease. J Hum Genet 2009, 5:15–39.
2. The MHC sequencing consortium: Complete sequence and gene map of a
human major histocompatibility complex. Nature 1999, 401:921–923.
3. Stewart CA, Horton R, Allcock RJ, Ashurst JL, Atrazhev AM, Coggill P,
Dunham I, Forbes S, Halls K, Howson JM, Humphray SJ, Hunt S, Mungall AJ,
Osoegawa K, Palmer S, Roberts AN, Rogers J, Sims S, Wang Y, Wilming LG,
Elliott JF, de Jong PJ, Sawcer S, Todd JA, Trowsdale J, Beck S: Complete
MHC haplotype sequencing for common disease gene mapping.
Genome Res 2004, 14:1176–1187.
4. Horton R, Gibson R, Coggill P, Miretti M, Allcock RJ, Almeida J, Forbes S,
Gilbert JG, Halls K, Harrow JL, Hart E, Howe K, Jackson DK, Palmer S, Roberts
AN, Sims S, Stewart CA, Traherne JA, Trevanion S, Wilming L, Rogers J, de
Jong PJ, Elliott JF, Sawcer S, Todd JA, Trowsdale J, Beck S: Variation analysis
and gene annotation of eight MHC haplotypes: the MHC Haplotype
Project. Immunogenetics 2008, 60:1–18.5. Traherne JA, Horton R, Roberts AN, Miretti MM, Hurles ME, Stewart CA,
Ashurst JL, Atrazhev AM, Coggill P, Palmer S, Almeida J, Sims S, Wilming LG,
Rogers J, de Jong PJ, Carrington M, Elliott JF, Sawcer S, Todd JA, Trowsdale
J, Beck S: Genetic analysis of completely sequenced disease-associated
MHC haplotypes identifies shuffling of segments in recent human
history. PLoS Genet 2006, 2:e9.
6. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK,
Pirmohamed M: HLA-B locus in Caucasian patients with carbamazepine
hypersensitivity. Pharmacogenomics 2006, 7:813–818.
7. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT,
Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH,
Huang YL, Lin JJ, Chen YT: Genetic susceptibility to carbamazepine-induced
cutaneous adverse drug reactions. Pharmacogenet Genom 2006, 16:297–306.
8. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W,
Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C,
Thurmond LM, Roses AD: Genetic variations in HLA-B region and
hypersensitivity reactions to abacavir. Lancet 2002, 359:1121–1122.
9. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A,
Mamotte C, Maxwell D, James I, Christiansen FT: Association between
presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to
HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727–732.
10. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F,
Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S: Predisposition
to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic
Hsp70-Hom variant. Proc Natl Acad Sci USA 2004, 101:4180–4185.
11. Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B,
Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D,
Mallal S, Shaefer M: Study of hypersensitivity to abacavir and
pharmacogenetic evaluation study team: high sensitivity of human
leukocyte antigen-b*5701 as a marker for immunologically confirmed
abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008,
46:1111–1118.
12. Dainichi T, Uchi H, Moroi Y, Furue M: Stevens-Johnson syndrome, drug-
induced hypersensitivity syndrome and toxic epidermal necrolysis
caused by allopurinol in patients with a common HLA allele: what
causes the diversity? Dermatology 2007, 215:86–88.
13. 1000 Genomes Project Consortium: A map of human genome variation
from population-scale sequencing. Nature 2010, 467:1061–1073.
14. Bentley G, Higuchi R, Hoglund B, Goodridge D, Sayer D, Trachtenberg EA,
Erlich HA: High-resolution, high-throughput HLA genotyping by next-
generation sequencing. Tissue Antigens 2009, 74:393–404.
15. Lind C, Ferriola D, Mackiewicz K, Heron S, Rogers M, Slavich L, Walker R,
Hsiao T, McLaughlin L, D’Arcy M, Gai X, Goodridge D, Sayer D, Monos D:
Next-generation sequencing: the solution for high-resolution,
unambiguous human leukocyte antigen typing. Hum Immunol 2010,
71:1033–1042.
16. Erlich RL, Jia X, Anderson S, Banks E, Gao X, Carrington M, Gupta N, DePristo
MA, Henn MR, Lennon NJ, de Bakker PI: Next-generation sequencing for
HLA typing of class I loci. BMC Genomics 2011, 12:42.
17. Wang C, Krishnakumar S, Wilhelmy J, Babrzadeh F, Stepanyan L, Su LF,
Levinson D, Fernandez-Viña MA, Davis RW, Davis MM, Mindrinos M: High-
throughput, high-fidelity HLA genotyping with deep sequencing.
Proc Natl Acad Sci U S A 2012, 109:8676–8681.
18. Lank SM, Wiseman RW, Dudley DM, O’Connor DH: A novel single cDNA
amplicon pyrosequencing method for high-throughput, cost-effective
sequence-based HLA class I genotyping. Hum Immunol 2010, 71:1011–1017.
19. Lank SM, Golbach BA, Creager HM, Wiseman RW, Keskin DB, Reinherz EL,
Brusic V, O’Connor DH: Ultra-high resolution HLA genotyping and allele
discovery by highly multiplexed cDNA amplicon pyrosequencing.
BMC Genomics 2012, 13:378.
20. Cocco E, Meloni A, Murru MR, Corongiu D, Tranquilli S, Fadda E, Murru R,
Schirru L, Secci MA, Costa G, Asunis I, Cuccu S, Fenu G, Lorefice L, Carboni
N, Mura G, Rosatelli MC, Marrosu MG: Vitamin D responsive elements
within the HLA-DRB1 promoter region in Sardinian multiple sclerosis
associated allele. PLoS ONE 2012, 7:e41678.
21. Thomas R, Apps R, Qi Y, Gao X, Male V, O’hUigin C, O’Connor G, Ge D, Fellay
J, Martin JN, Margolick J, Goedert JJ, Buchbinder S, Kirk GD, Martin MP,
Telenti A, Deeks SG, Walker BD, Goldstein D, McVicar DW, Moffett A,
Carrington M: HLA-C cell surface expression and control of HIV/AIDS
correlate with a variant upstream of HLA-C. Nat Genet 2009,
41:1290–1294.
Hosomichi et al. BMC Genomics 2013, 14:355 Page 16 of 16
http://www.biomedcentral.com/1471-2164/14/35522. Elsner HA, Bernard G, Eiz-Vesper B, de Matteis M, Bernard A, Blasczyk R:
Non-expression of HLA-A*2901102 N is caused by a nucleotide
exchange in the mRNA splicing site at the beginning of intron 4.
Tissue Antigens 2002, 59:139–141.
23. Tamouza R, El Kassar N, Schaeffer V, Carbonnelle E, Tatari Z, Marzais F,
Fortier C, Poirier JC, Sadki K, Bernaudin F, Toubert A, Krishnamoorthy R,
Charron D: A novel HLA-B*39 allele (HLA-B*3916) due to a rare mutation
causing cryptic splice site activation. Hum Immunol 2000, 61:467–473.
24. Dubois V, Tiercy JM, Labonne MP, Dormoy A, Gebuhrer L: A new HLA-B44
allele (B*44020102S) with a splicing mutation leading to a complete
deletion of exon 5. Tissue Antigens 2004, 63:173–180.
25. Shiina T, Suzuki S, Ozaki Y, Taira H, Kikkawa E, Shigenari A, Oka A, Umemura
T, Joshita S, Takahashi O, Hayashi Y, Paumen M, Katsuyama Y, Mitsunaga S,
Ota M, Kulski JK, Inoko H: Super high resolution for single molecule-
sequence-based typing of classical HLA loci at the 8-digit level using
next generation sequencers. Tissue Antigens 2012, 80:305–316.
26. Li H, Durbin R: Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 2009, 25:1754–1760.
27. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis
G, Durbin R: The sequence alignment/Map format and SAMtools.
Bioinformatics 2009, 25:2078–2079.
28. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A,
Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA: The genome
analysis toolkit: a MapReduce framework for analyzing next-generation
DNA sequencing data. Genome Res 2010, 20:1297–1303.
29. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis
AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM,
Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler D, Daly MJ: A framework
for variation discovery and genotyping using next-generation DNA
sequencing data. Nat Genet 2011, 43:491–498.
30. Kent WJ: BLAT–the BLAST-like alignment tool. Genome Res 2002, 12:656–664.
31. Nagasaki H, Mochizuki T, Kaminuma E, Watanabe S, Morizaki S, Kodama Y,
Saruhashi S, Takagi T, Okubo K, Nakamura Y: DDBJ read annotation
pipeline: a cloud computing based pipeline for high-throughput analysis
of next generation dequencing data. DNA Res 2013. In press.
doi:10.1186/1471-2164-14-355
Cite this article as: Hosomichi et al.: Phase-defined complete
sequencing of the HLA genes by next-generation sequencing. BMC
Genomics 2013 14:355.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
